Previous close | 11.20 |
Open | 11.20 |
Bid | 11.40 |
Ask | 14.40 |
Strike | 17.50 |
Expiry date | 2024-11-15 |
Day's range | 11.20 - 11.20 |
Contract range | N/A |
Volume | |
Open interest | N/A |
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on May 31, 2024, the company granted equity awards to four new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c
Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Troy Lister, Ph.D., currently serving as Verve’s senior vice president, research and early development, has been appoint
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in fireside chats during the following investor conferences: Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1 p.m. ET in New York, NYGoldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 8 a.m